Thursday, October 31, 2013
Publication and contact
Transgenic mouse model of
overexpression in Parkinson's disease (PD)
transgenic mouse PD model could help define early defects in dopaminergic
neurons and help evaluate candidate therapeutic strategies. The mice show
1.9-fold increased expression of human SNCA over endogenous levels at
developmental stages and more closely mimic PD-relevant pathology compared
with existing models. In these mice, high levels of SNCA resulted in a
persistent decrease of dopamine release in the brain that
occurred prior to the loss of dopamine neurons or onset of motor deficits.
Next steps could include using the model to evaluate early intervention
strategies for PD.
SciBX 6(42); doi:10.1038/scibx.2013.1201
Published online Oct. 31, 2013
Patent and licensing status
Janezic, S. et al. Proc.
Natl. Acad. Sci. USA; published online Sept. 30, 2013;
Contact: Richard Wade-Martins, University of Oxford, Oxford,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]